The current litera ture recomm ends that pa tients who have symptoms of sleep disordered breathing should be evaluatedfo r hypothyroidism . Thyroid hormone replacement therapy has been repo rted by some authors to be effe ctive in trea ting obstructive sleep apnea in hypo thyroid patients. The present study prospectively evaluated the prevalenc e of hypothyroidism in 1,000 consec utively presentin g pa tients who came to the office fo r evaluation of snoring or obs tructive sleep apn ea syndrome. The authors also examined the efficacy of treatment fo r hypothyro idism on sleep apnea in patients with bot h disorders.
Introduction
Some researc hers have found that thyroid hormone replacement therap y ameliorates symptoms of obstructi ve sleep apnea in patients with clinical hypothyroidism. '? Other inves tigators have reported little bene fit from thyroid replacement in these patients.' Although patients who have myxedema or symptomatic hypothyroid ism have a high incidence of sleep apnea.t-" patient s with sleep apnea syndro me appear to have the same prevalenc e of hypothyroidi sm as the general popul ation." Nonet heless , routine screenin g for hypothyroidism has been recommended for patient s with obstructive sleep apnea syndrome (OSAS). 6 .7The present study examine s the prevalenc e of hypothyroidi sm in patients evaluated for sleep disordered breathing and asses ses the efficacy of treatment of the hyp othyroid state in a large case series .
Materials and methods
Thyroid function testing (measure ment ofthyroid-stimulating hormone [TSH]) was recommended for essentially all patient s seen for evaluation of snoring or sleep apnea syndrome by the senior author. Pati ent s who had a diagnosis of primary snoring without apnea and without any symptoms of hypoth yroid ism were not tested. Patient s who had eleva ted levels of TSH were further evaluated for hypothyroidism by measurements of serum free thyroxin (T) levels and other appropria te tests. Medical records of patients whose thyroid test results were abnormal were reviewed retros pectively. Patients were classified either as being euthyroid or as having subclinical hypothyroidism (mildly eleva ted TSH with normal T) , known hypoth yroid ism (which was being treated with thyroid hormone replace ment therapy at the time of the eva luation), clin ical hypothyroidism (TSH >I0 mUlL and low T) , or subclinica l hyperth yr oidism (low TSH and normal T) . asAS was defined as the presenc e of sleep apnea symptoms and a respir atory distu rbance index (RDI) of 10 or more on polysomnography (PSG), as evaluated by standard criteria"; RDI is calculated by aver aging the numb er of apneic and hypopneic events per hour of sleep .
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THYROID TESTING AND THYROID HORMONE REPLACEMENT IN PATIENTS W ITH SLEEP DISO RDERED BREATHING Primary snoring was defined as the presence of significa nt sno ring and an RDI of less than 10 on PS G or the prese nce of sig nificant reg ular snori ng on audiotape recording without any symptoms of sleep apnea .
The four patients wit h both clinica l hypoth yroid ism and OSAS were treated with thyroid horm one rep lacement by an endocrino log ist. After these patient s became euthyroid , PSG was repea ted 4 to 12 months later. Preand postt reatm ent PSG res ults were compare d, and a statistical analysis was performed with the stude nt's t test (statistical sig nifica nce : p<0.05).
Results
Between Janu ary 1993 and March 1996, an eva luat ion of sleep disord ered breathing was perform ed on 1,000 consecutive ly presenting patients (mea n age: 47 ; 80% men ; mean bod y mass index : 32 kg/m "). Of these patient s, 834 were tested for hypothyroid ism. Th e remai ning 166 patients eith er had refuse d thyroid scree ning, had sympto ms of primary snoring onl y (the refore, thyro id screening was not recommended), or underwent testing elsew here and were lost to follow up.
OSAS was identi fied in 542 of the 834 patients (65%) . OSAS and two with nonapn eic snoring). Tw elve patient s ( 1.4%) had kno wn hypoth yroidi sm . Of these 12, nine with OSAS were euthyroid, two with nonapneic snoring were euthyroid, and one with OSAS had a markedly eleva ted TSH level; this last patient was treated with a high er dose of thyroid hormone, but he did not return for a repeat PSG. Seventeen patients (2.0%) with subclinical hyperthyroidism had a low TSH but were asymptomatic and had a norm al T 4 level.
Ten patient s (1.2%) were newl y diagnosed with clinical hypothyroidi sm. Of these, five were primary snorers (two by history and three by PSG ), one had symptoms of OSAS but refused PSG , and four had OSAS confirmed on PSG . These four OSAS patients were placed on thyroid replacement hormone by an endocrinologist , and their sleep study was repeated at least 4 month s after they became euthyroid (range: 4-12 mo). The five patient s with primary snoring were also treated with thyroid replac ement hormone by an endocrinologist. After 6 to 12 month s of treatment , only one of these five patients reported any significant reduction in snoring. The patient who refused a sleep study was lost to followup.
The four newly diagnosed hypothyroid patients with OSAS had a mean pretreatment RDI of 64.4 (± 19.4) and a lowest oxygen saturation level of 80.3 % (±8 .7%). After treatment, their mean RDI was 55 .6 (±36.3) and their lowest oxyge n saturation was 75 .8% (± 13.3%) (table) . The difference bet ween the pre-and posttre atment results was not statistically significant (one patient did lowe r his RDI from 44 to 18). There were also no statistically significant differences between pre-and posttreatment apnea index, body mass index, sleep efficiency, and sleep architectur e. The OSAS patients were comp ared with nonapneic snorers. Of the 270 patients with non apneic snorin g, 261 (96.7%) had normal TSH level s, two patients (0.7%) had subclinical hypothyroidism, two patients had known hypothyroidism, and five patient s (1.9% ) were newly diagnosed with clinical hypothyroidism . Of the 542 patient s with OSAS , 524 patients (96.7 %) had normal TSH levels, three patient s (0.6%) had subclinical hypothyroidism, ten patients (1.8%) had known hypothyroidi sm, and five patients (0.9%) had newly diagnosed clinical hypoth yroidism. The re was no significant difference between the two groups in the percentage of patients who had clinical or subclinical hypothyroidism.
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Discussion
The earliest biochemical evidence of hypothyroidism is a mild elevation of the serum TSH level. When levels of circulating thyroid hormone (T 3 and T 4 ) are normal in these patients, their condition has been termed subclinical hypoth yroidism or compensated hypothyroidism . However, as the disease progresses, the levels of serum T 4 , and later T 3 , begin to decrease. As these circulating thyroid hormone levels fall, many patients exhibit signs and symptoms of hypothyroidism. The term myxedema is generally used to describe overt manifestations of hypothyroidism.
Whether or not subclinical hypothyroidism should be treated is still open to debate. As part of this study , we consulted four endocrinologists regarding how to manage our patients with newly diagnosed subclinical hypothyroidism. All four recommended no active treatment. Their prevailing belief was that mild thyroid dysfunction has nothing to do with sleep disordered breathing.
While several studies have examined the prevalence of OSAS in patients with myxedema or clinical hypothyroidism.l -" only three studies have evaluated the prevalence of hypothyroidism in patients with OSAS. Lin 10 Of these four hypothyroid patients, two were already on thyroid replacement hormone therapy. In our study , 10 of 842 patients (1.2%) who were referred for evaluation of sleep disordered breathing were diagnosed with clinical hypothyroidism (1.9 % of the primary snorers and 0.9 % of those with sleep apnea) .
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and 1.2% of 86 men were identified with a new diagnosis of hypothyroidism." It appears that the prevalence of hypothyroidism in patients who are being evaluated for OSAS, in patients with confirmed OSAS, and in patients with nonapneic snoring falls within the range of the prevalence of hypothyroidism in the general population-that is, within the range of 0.8 to 5.9 %.
Routine screening for hypothyroidism has been recommended as part of the workup of obstructive sleep apnea in the sleep medicine literature.v? As the basis for this recommendation, reference has been made to a study by Rajagopal et aI, who reported a marked improvement in sleep apnea in nine hypothyroid patients during thyroid hormone replacement therapy .' Their mean apnea frequency fell from 71. . 18 In a study of two patients who presented with depression, McNamara et al found subclinical hypothyroidism in association with sleep apnea. 19 Thyroid hormone replacement led to a resolution of both apnea and depression.
In a more detailed report, Lin et al described the effects of thyroid replacement therapy on five patients with hypothyroidism and sleep apnea.' After 4 months of therapy , their apnea index decreased from 35.8 (±39.4; range: 7.9-97 .2) to 3.4 (±3.4; range: 0.8-9.1). The benefit of hormone replacement in these patients was still evident during testing performed at 12 months. Although their frequency of snoring had increased significantly at 4 month s, it had decreased at 12 months.
In contrast with these positive results , Grunstein and Sullivan studied eight patients after treatment with levothyroxine." Even after the eight patients became euthyroid, six of them (75%) still had persistent sleep apnea . Their mean pretreatment apnea index, which was 51 (±6), fell only a few points to 45 (±8) after treatment. Grunstein Afterdaily oral doses of 750mg/kg(mice)and 250mg/kg(rat s) wereadministered for upto 2 years, there was no evidencethat ciprotloxacin hadanycarcinogenic or tumorigeni c effects in these species. No longtermstudiesof CIPRO' HC OTI Csuspension havebeenperformedto evaluate carcinogenic potential. Fertili ty studies performedin rat s at oral doses of ciprofloxacin upto 100mg/kg/day revealed noevidence of impairment. Thi s would beover 1000 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a pati enttreated with CIPRO' HCOTIC twice perday. Long term studies have notbeenperformedto evaluate thecarcinog eni c potent ialortheeffect onfertility of topical hydrocorti sone. Mut agenicity studieswith hydro corti sonewere negati ve. Pregnancy: Teratogenic Effects. Pregnancy Category C: Reproduction studies have been perf ormed in rats and mi ce using oral doses of upto 100mglkg and IV doses up to 30 mg/kg and have reveaiednoevidenceof harm to the fetus asa result of ciprofloxacin. In rabbits, ciprofloxacin (30and 100mg/kgorall y) producedgastrointestinaldisturbances resulting in maternal weight loss and anincreasedincidence of abortion, butno teratogenicity was observedateither dose. Atter intravenousadministrationofdoses upto 20mglkg, no maternal toxicity was produced in the rabbit, and no embryotoxicity or teratogenicity was observed. Coiticosteroids are generallyteratogenic iniaboratory animalswhenadmini stered systemicailyat rel ati vely low dosage level s, The more potent corticosteroidshave beenshown to beteratogenic alter dermal applicationin iaboratory animal s.
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ADVERSE REACTIONS
Our study co nfirms the im pressions of Grun stein and Sull ivan inasmuch as treatm ent of hypothyroid ism impro ved the RDI in only one of four patient s (25 %).4Even though the one improved patient had a reduction in RDI of more than 50 %, he still continued to experience sig nificant apnea. When reviewing our result s and other reports in the literature, it is clear that thyroid hormone repl acement migh t not ameliora te obstructive sleep apnea .
Our study does not address the issue of the prevalence of sleep apne a in patients with newly diag nose d hypothyroidism. Lin et al found that 5 of 20 (25%) hypothyroid patient s had sleep apnea ," On the other hand, Raj agopal found 9 of 11 (82%) patient s to be so affec ted.' Peltt ari et aP compared hypothyroid patient s and controls who underwent sleep studies and found that nocturnal bre athin g abnormalities were com mon in both groups (50 and 29 %, respecti vely). They found that 7.7 % of hypothyro id patient s and 1.5% of controls had severe obstructive apneas; however, statistica l analysis revealed that the variance bet ween the groups was prim arily dependent on obesi ty and male gen der. It is likely that hypoth yroidi sm can co ntribute to the development of OSAS , but it is uncl ear whether its effect is independ ent or is relat ed to other factors suc h as obe sity.
In 1996, the average charge for a thyroid function test (TSH) at our clin ical laboratory was $60. Th e cos t of testin g our entire study gro up was more than $50,000. Although the cost of an individual TSH test is less than the cost of a sleep study , a CP AP machine, or surgery , it is noneth eless a significa nt amount of money, an amo unt that proved to be spent to little ava il. Our rout ine scree ning of 1,000 patient s resulted in only a modest benefit for only two patient s. Eliminating routine thyroid scree ning in patients who present for an evaluation of sleep disordered breathing co uld save a large numb er of health care dolla rs.
The result s of our study lead us to three concl usions: I) Th e prevalence of clinica l hypoth yroid ism in patients seen for an eva luation of sleep disordered breathing is no grea ter than that seen in the ge nera l popul ation . 2) Th yroid replace ment therapy in hypothyro id patient s with obstruc tive sleep apnea res ults in little or no improvement in apnea symptoms. Th erefore, 3) rout ine scre ening of thyroid function is not indic ated for these patient s.
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